Literature DB >> 7828975

Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis.

Y Yasunaga1, Y Shinomura, S Kanayama, M Yabu, T Nakanishi, Y Miyazaki, Y Murayama, J J Bonilla-Palacios, Y Matsuzawa.   

Abstract

This study examined the effects of eradication of Helicobacter pylori (H pylori) infection on gastric mucosal morphology and acid secretion. Sixteen H pylori positive patients with enlarged gastric body folds were divided into two groups: (a) patients with moderate enlargement (fold width: 6 to 10 mm, n = 8) and (b) patients with severe enlargement (> 10 mm, n = 8). After successful treatment, gastric body fold width was reduced in both groups (p < 0.01) with an associated decrease in inflammatory infiltrates in the body mucosa (p < 0.01 and p < 0.05). Basal acid output and tetragastrin stimulated maximal acid output (mean (SEM)) in all 16 patients significantly increased from 1.1 (0.5) to 2.9 (0.9) mmol/h (p < 0.05) and from 5.4 (1.3) to 18.7 (2.3) mmol/h (p < 0.01), respectively, with a significant decrease in fasting serum gastrin concentrations, from 127.1 (16.1) to 59.6 (3.8) pg/ml (p < 0.01). The increase in acid secretion after eradication of H pylori was more noticeable in the severe group, who had shown lower acid secretion and higher serum gastrin concentrations (p < 0.05) before eradication, than the increase seen in the moderate group. The decreases in ammonia nitrogen content seen after eradication were significant in basal (from 0.91 (0.17) to 0.37 (0.08) mmol/h, p < 0.05) and stimulated gastric secretions (from 1.57 (0.19) to 0.37 (0.13) mmol/h, p < 0.01), although these changes were too small to explain the increases in basal acid output and maximal acid output. These results suggest that inflammation of the gastric body mucosa caused by H pylori infection is associated with enlarged gastric body folds and inhibition of acid secretion in H pylori positive patients with enlarged gastric body folds.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7828975      PMCID: PMC1375614          DOI: 10.1136/gut.35.11.1571

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Improvement in gastric secretion by the inclusion of tetracyclines in therapeutic schedules for Helicobacter pylori-associated active chronic gastritis.

Authors:  R León-Barúa; R Berendson; C Rodriguez; R H Gilman; S Recavarren; J Cok
Journal:  Am J Gastroenterol       Date:  1991-07       Impact factor: 10.864

2.  Hyperplastic gastropathy. Clinicopathologic correlation.

Authors:  R A Komorowski; J G Caya
Journal:  Am J Surg Pathol       Date:  1991-06       Impact factor: 6.394

3.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

4.  Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism.

Authors:  S Levi; K Beardshall; I Swift; W Foulkes; R Playford; P Ghosh; J Calam
Journal:  BMJ       Date:  1989-12-16

5.  Enlarged gastric folds in association with Campylobacter pylori gastritis.

Authors:  S Morrison; B B Dahms; E Hoffenberg; S J Czinn
Journal:  Radiology       Date:  1989-06       Impact factor: 11.105

6.  Radioimmunoassay of gastrin.

Authors:  R S Yalow; S A Berson
Journal:  Gastroenterology       Date:  1970-01       Impact factor: 22.682

7.  Serum pepsinogens as a screening test of extensive chronic gastritis.

Authors:  K Miki; M Ichinose; A Shimizu; S C Huang; H Oka; C Furihata; T Matsushima; K Takahashi
Journal:  Gastroenterol Jpn       Date:  1987-04

8.  Effect of a Campylobacter pylori protein on acid secretion by parietal cells.

Authors:  D R Cave; M Vargas
Journal:  Lancet       Date:  1989-07-22       Impact factor: 79.321

9.  Rapid urease test in the management of Campylobacter pyloridis-associated gastritis.

Authors:  B J Marshall; J R Warren; G J Francis; S R Langton; C S Goodwin; E D Blincow
Journal:  Am J Gastroenterol       Date:  1987-03       Impact factor: 10.864

10.  Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori.

Authors:  S F Moss; J Calam
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

View more
  18 in total

1.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

2.  Increased production of interleukin 1 beta and hepatocyte growth factor may contribute to foveolar hyperplasia in enlarged fold gastritis.

Authors:  Y Yasunaga; Y Shinomura; S Kanayama; Y Higashimoto; M Yabu; Y Miyazaki; S Kondo; Y Murayama; H Nishibayashi; S Kitamura; Y Matsuzawa
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

Review 3.  Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?

Authors:  J Labenz; P Malfertheiner
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

4.  Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese.

Authors:  Y Kinoshita; C Kawanami; K Kishi; H Nakata; Y Seino; T Chiba
Journal:  Gut       Date:  1997-10       Impact factor: 23.059

5.  Effectiveness of acid suppression in preventing gastroesophageal reflux disease (GERD) after successful treatment of Helicobacter pylori infection.

Authors:  T Rokkas; S D Ladas; C Liatsos; E Panagou; A Karameris; S A Raptis
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

6.  Predictive findings for Helicobacter pylori-uninfected, -infected and -eradicated gastric mucosa: validation study.

Authors:  Kazuhiro Watanabe; Naoyoshi Nagata; Ryo Nakashima; Etsuko Furuhata; Takuro Shimbo; Masao Kobayakawa; Toshiyuki Sakurai; Koh Imbe; Ryota Niikura; Chizu Yokoi; Junichi Akiyama; Naomi Uemura
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

7.  The effect of intragastric ammonia production on titratable gastric acid output in Helicobacter pylori-infected patients with chronic gastritis.

Authors:  Bogdan Cylwik; Jan W Dlugosz; Andrzej Kemona; Maciej Szmitkowski
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

8.  The significance of cagA(+) Helicobacter pylori in reflux oesophagitis.

Authors:  V J Warburton-Timms; A Charlett; R M Valori; J S Uff; N A Shepherd; H Barr; C A McNulty
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

9.  Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole.

Authors:  D Gillen; A A Wirz; W D Neithercut; J E Ardill; K E McColl
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

10.  Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole.

Authors:  E F Verdú; D Armstrong; J P Idström; J Labenz; M Stolte; G Dorta; G Börsch; A L Blum
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.